AAVantgarde Bio is a clinical stage, Italian headquartered, international biotechnology company that has developed two proprietary Adeno-Associated Viral (AAV) vector platforms to address the gene therapy cargo capacity limitations of AAV vectors. The AAVantgarde platforms could be used to deliver large genes to ocular and non-ocular tissues. The company is validating the platforms in two programs: Usher Syndrome Type 1 B associated retinitis pigmentosa (Usher1B) and Stargardt disease.
| Headquarters | Milan, Italy |
| Website | aavantgardebio.com |
| Pipeline Status | Clinical |
| AAVantgarde Bio |